Delving into the Latest Updates on Recombinant erythropoietin(Bio-Gal) with Synapse

Overview

Basic Info

Drug Type

Colony-stimulating factors

Synonyms

EPO, Recombinant erythropoietin, rHuEPO

Target

EPO receptor

Action

agonists, stimulants

Mechanism

EPO receptor agonists(Erythropoietin receptor agonists), Erythropoiesis stimulants(Erythropoiesis stimulants)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases

Active Indication-

Inactive Indication

Multiple Myeloma

Originator Organization

Bio-Gal

Active Organization-

Inactive Organization

XTL Biopharmaceuticals Ltd.

License Organization-

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

ESTUDIO MULTICENTRICO PROSPECTIVO, DOBLE CIEGO, CONTROLADO CON PLACEBO, ALEATORIZADO, DE TRES GRUPOS PARALELOS PARA EVALUAR LA EFICACIA Y SEGURIDAD DEL TRATAMIENTO CON ERITROPOYETINA RECOMBINANTE HUMANA EN LA PREVENCIÓN DE LA NEFROTOXICIDAD ASOCIADA A LA UTILIZACIÓN DE CONTRASTES YODADOS EN PACIENTES CON ALTO RIESGO DE DISFUNCIÓN RENAL. - Nefroprotección con rHuEPO en nefropatía por contraste

Start Date18 Feb 2008

Sponsor / Collaborator-

EUCTR2007-005831-27-IT

/ Unknown statusNot ApplicableIIT

Use of rHuEpo before autologous hematopoietic stem cell transplantation in patients affected by multiple myeloma, non Hodgkin disease and breast cancer to reduce transfusional requirement after myeloablative conditioning. A monocentric, phase III, open study. - ND

Start Date09 Nov 2007

Sponsor / Collaborator-

100 Clinical Results associated with Recombinant erythropoietin(Bio-Gal)

Login to view more data

100 Translational Medicine associated with Recombinant erythropoietin(Bio-Gal)

Login to view more data

100 Patents (Medical) associated with Recombinant erythropoietin(Bio-Gal)

Login to view more data

7,116

Literatures (Medical) associated with Recombinant erythropoietin(Bio-Gal)

31 Dec 2025·RENAL FAILURE

Effect of roxadustat on lowering blood lipids in peritoneal dialysis patients with anemia

Article

Author: Zang, Xiujuan ; Huang, Xiaomin ; Ma, Yuhua ; Zhang, Chunyan ; Ruan, Yilin ; Chen, Nan ; Wang, Yi ; Yu, Geping ; Xu, Tian ; Xie, Jingyuan ; Ren, Hong ; Qi, Hualin ; Mi, Xiuhua ; Liu, Na

OBJECTIVES:

To observe the effect of roxadustat on lowering blood lipids in peritoneal dialysis (PD) patients beyond treating anemia.

METHODS:

In a prospective, multicenter clinical study, we randomly assigned (in a 1:1 ratio) 100 PD patients who had received erythropoiesis-stimulating agent therapy for at least 4 weeks to receive either roxadustat or erythropoietin (EPO) for 48 weeks. The blood lipids, hemoglobin, blood pressure, blood glucose, iron metabolism and inflammatory factors were compared between the two groups at 0, 2, 4, 8, 12, 16, 20, 24 and 48 weeks, respectively.

RESULTS:

At start of switching to roxadustat, hemoglobin seemed to rise a little faster (102.8 ± 15.4 vs. 97.1 ± 17.3 g/L at 2 weeks, p > 0.05), but there was no significant difference in hemoglobin change between the two groups over the course of observation (p = 0.185). At the early stage of the study (12 weeks), the transferrin saturation (TSAT) of roxadustat group decreased significantly from the baseline (32.7 (20.6) vs. 22.1 (18.7)%, p = 0.001). At the end of the study period (48 weeks), total cholesterol (3.89 ± 0.92 vs. 4.52 ± 1.14 mmol/L, p = 0.012), low density lipoprotein cholesterol (2.24 ± 0.74 vs. 2.63 ± 0.82 mmol/L, p = 0.045) and triglyceride (1.35 (0.86) vs. 1.89 (1.27) mmol/l, p = 0.013) in roxadustat group were significantly lower than those in EPO group.

CONCLUSIONS:

Roxadustat not only can improve anemia and iron metabolism, but also can reduce serum cholesterol and triglyceride levels in PD patients after switching from the EPO.

01 Dec 2025·MOLECULAR BIOLOGY REPORTS

Therapeutic effects of erythropoietin-alginate/chitosan hydrogel on impaired male rat fertility after spinal cord injury

Article

Author: Rasekh, Morteza ; Akbari, Ghasem ; Sadeghinezhad, Javad ; Gilanpour, Hassan ; Mortazavi, Pejman

BACKGROUND:

Infertility is a significant issue in spinal cord injury (SCI) patients. Men with SCI often experience erectile and ejaculatory dysfunctions, and low sperm quality leading to impaired fertility. In this study, we investigated the effectiveness of Erythropoietin (EPO)alginate/chitosan (CH-AL) hydrogel on SCI-induced male rat infertility.

METHODS:

Twenty-four male Wistar rats were divided into three groups: Sham, SCI-induced group without any further intervention (Negative control, NC), and a treatment group receiving 10,000 IU/kg EPO-CH/AL hydrogel (EPO group), immediately following SCI induction. Sperm parameters, oxidative stress markers, apoptosis, and histopathological changes in animal testes were analyzed.

RESULTS:

Sperm viability and motility significantly decreased in the NC group compared to the sham group (p < 0.01). Treatment with 10,000 IU/kg EPO-CH/AL hydrogel significantly improved sperm viability and motility compared to the NC group (p < 0.05). Malondialdehyde (MDA) and Superoxide dismutase (SOD) levels were elevated and reduced, respectively, in the NC group compared to the sham group. Treatment with EPO-CH/AL hydrogel group, significantly decreased MDA level and increased SOD levels compared to the NC group (p < 0.05). Apoptosis analysis revealed upregulation of Bcl-2 and downregulation of Bax genes in EPO-CH/AL hydrogel compared to the NC group (p < 0.05). Histological analysis showed that the EPO-CH/AL hydrogel improved depletion of germ cell population and Luminal spaces compared to NC group but did not fully restore normal histology.

CONCLUSION:

EPO-CH/AL hydrogel effectively improves sperm viability and motility, reduces oxidative stress, and mitigates apoptosis, demonstrating its potential as a therapeutic strategy for SCI-induced infertility.

01 Dec 2025·INFLAMMATION RESEARCH

Effects of remote ischemic preconditioning and/or erythropoietin on lung injury induced by skeletal ischemia reperfusion: role of the NLRP3 inflammasome

Article

Author: Ali, Mennatallah A ; El-Mas, Mahmoud M ; Elsokkary, Nahed H ; Khalifa, Asmaa A ; Elblehi, Samar S

BACKGROUND AND OBJECTIVES:

Remote ischemic preconditioning (RIPC) diminishes multi-organ failure induced by skeletal muscle ischemia and reperfusion (S-I/R). The current study investigated whether skeletal RIPC protection against S-I/R-induced acute lung injury (ALI) could be facilitated following simultaneous exposure to the glycoprotein hormone erythropoietin (EPO) in rats and whether this interaction is modulated by the NLRP3 inflammasome.

METHODS:

S-I/R challenge was performed by 3-h ischemia followed by 3-h reperfusion of the right hindlimb, whereas RIPC involved three 20-min brief consecutive I/R cycles of the contralateral hindlimb.

RESULTS:

The lung injurious response to S-I/R was verified by: (i) decreases in minute respiratory volume (MRV), forced expiratory volume 1 (FEV1) and functional vital capacity (FVC), (ii) increases in respiratory rate (RR), (iii) falls in lung surfactant protein-D (SP-D) and rises in of lung plasminogen activator inhibitor-1 (PAI-1) and intercellular adhesion molecule-1 (ICAM-1), and (iv) disruption of alveolar architecture. These lung defects were partially amended by RIPC or EPO (500 or 5000 IU/kg). Further, the prior exposure to RIPC plus EPO-500 was more effective than separate interventions in rectifying ALI damages. Molecularly, the dual RIPC/EPO-500 regimen was also more effective in reversing the S-I/R-associated increments in pulmonary expressions of NLRP3 and related inflammatory (TLR4, MyD88, TRAF, NF-κB, TNF-α, IL-1β, and IL-18), apoptotic (ASC, procaspse-1, caspase-1), and microRNA signals (increases in miR-21 and decreases miR-495).

CONCLUSION:

These findings suggest a pivotal role for the suppression of NLRP3 inflammasome and interconnected cellular offenses in the augmented therapeutic potential of the RIPC/EPO-500 regimen against S-I/R-induced ALI.

1

News (Medical) associated with Recombinant erythropoietin(Bio-Gal)

23 May 2021

·www.globenewswire.com

HAGENS BERMAN Reminds FibroGen (FGEN) Investors of

SAN FRANCISCO, May 23, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now. Class Period: Oct. 18, 2017 – Apr. 6, 2021Lead Plaintiff Deadline: June 11, 2021Visit: Contact An Attorney Now: FGEN@hbsslaw.com 844-916-0895 FibroGen, Inc. (NASDAQ: FGEN) Securities Fraud Action: The complaint centers on FibroGen’s presentation of false data of roxadustat to make the anemia drug look safer than it is. Throughout the Class Period, FibroGen touted the prospects of roxadustat. A key selling point for the drug was its purported heart safety as compared to standard of care erythropoietin (EPO) injectable therapies, which cannot be proscribed to a variety of patients at risk of major cardiac events. To support this marketing edge, FibroGen presented data from phase 3 trials purportedly showing roxadustat was safer than EPO, among other at risk populations, in incident dialysis patients. But after the market closed on Apr. 6, 2021, FibroGen stunningly admitted to altering stratification factors to make roxadustat’s hazard ratios indicate lower risk relative to EPO. As a result of the data manipulation, FibroGen CEO Enrique Conterno admitted that the company can no longer say its drug was safer than EPO in incident dialysis patients. In response to this news, several analysts slashed their FibroGen share price targets and reduced their investment recommendations. On this news, the Company’s share price fell over 43%, to close at $19.74 per share on Apr. 7, 2021. Shares continued to fall 5% on Apr. 8, 2021, on heavy volume. “We’re focused on investors’ losses and proving FibroGen senior management intentionally manipulated the safety-related data for its anemia drug,” said Reed Kathrein, the Hagens Berman partner leading the investigation. If you are a FibroGen investor and have significant losses, or have knowledge that may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman. Whistleblowers: Persons with non-public information regarding FibroGen should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email FGEN@hbsslaw.com. About Hagens BermanHagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw. Contact:Reed Kathrein, 844-916-0895

100 Deals associated with Recombinant erythropoietin(Bio-Gal)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple Myeloma	Phase 1	-	XTL Biopharmaceuticals Ltd.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASN2018	Not Applicable	Hgb levels	60	Daily EPO administration	wcvemssted(gcxjcbqpug) = bgjmnsmakv nnjcholywj (yivgoznecu )	Positive	23 Oct 2018
				Thrice weekly EPO administration	wcvemssted(gcxjcbqpug) = fpettgbosg nnjcholywj (yivgoznecu )
ASN2015	Not Applicable	-	4	Erythropoietin (rHuEpo)	eygfcsolrn(pjuscrgoxt) = increased near term without need of medication yqgduamrao (xkxknkdaem ) View more	Positive	03 Nov 2015
				Iron supplements (IS)
EuCliD (ERA2015)	Not Applicable	-	-	EPO (Lean Tissue Index (LTI))	cggcqgdggj(geisxzbxan) = fdmasbfdnl dhtiwvtuno (ixnzcoikge )	Positive	21 May 2015
				EPO (Fat Tissue Index (FTI))	cggcqgdggj(geisxzbxan) = jhfcgpyjxu dhtiwvtuno (ixnzcoikge )
ARVO2013	Not Applicable	-	-	EPO	uisbwpjiwp(ohsoyfanuf) = cacocvwbri bybmpjyzke (vyrggogckw )	-	01 Jun 2013
				VEGF	uisbwpjiwp(ohsoyfanuf) = bdlnzhpklp bybmpjyzke (vyrggogckw )
ASN2011	Not Applicable	Anemia	55	Epoetin beta (EB)	zdypwukxlv(jeiyxeyxtf) = mvczzryudo pvobzgqyoc (ydwenqffuk )	Positive	08 Nov 2011
				EPO (No Treatment (NT))	zdypwukxlv(jeiyxeyxtf) = plzvonhtgc pvobzgqyoc (ydwenqffuk )
JET study (ASN2010)	Not Applicable	Chronic Kidney Diseases hemoglobin \| serum creatinine	-	EPO treatment	zkefmrrolc(rqnvbglklb): HR = 0.65 (95% CI, 0.54 - 0.78)	Positive	16 Nov 2010
				Non-EPO treatment
ASN2010	Not Applicable	-	35	EPO	mkkmwxzpbt(kbpmgoowhv) = jczetaivth uyttseqhlz (rapmwjvqox )	Positive	16 Nov 2010
				IV iron ferric gluconate	xhaqgdamkz(ohqtbwrkfo) = qvfxywoigj yxssmguhhg (dgsgrvsvqn ) View more
Pubmed \| Ophthalmic Surg Lasers Imaging Retina	Not Applicable	Diabetic macular oedema	5	Intravitreal Erythropoietin Therapy	lbtunyrjbn(djwvcphdgt) = vlmfcatdeo rxnearbbqi (iawfuvyppb )	Positive	01 Jan 2010
ASCO2007	Not Applicable	Neoplasms	25	rHuEPO treatment	vmpsygcvhn(vhtiuhrrqw) = pzwlhwnavl wmthvdkbwk (adouyzhumt )	Negative	20 Jun 2007
				Human recombinant erythropoietic agents (rHuEPO) (Control)	vmpsygcvhn(vhtiuhrrqw) = zebqtcrheh wmthvdkbwk (adouyzhumt )

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data